PRIA Logo™
S3522119th CongressWALLET

No Red Tape For Addiction Treatment Act

Sponsored By: Senator Hassan, Margaret Wood [D-NH]

Introduced

Summary

This bill would require State Medicaid programs to cover at least one formulation of every medication and biological product for treating opioid use disorder without prior authorization or limits on dosage. It would also require coverage of long‑acting injectable forms when available and would not stop States from keeping a formulary that meets existing federal rules.

Show full summary
  • People with opioid use disorder and their families would face fewer paperwork hurdles to start or continue medication‑assisted treatment because at least one form of each drug must be covered with no prior authorization and no dosage caps.
  • State Medicaid programs would need to change their plans or waivers to meet the new coverage rule. The requirement would apply to medical assistance provided on or after 1 year after enactment, and States that need new legislation get a limited implementation delay.
  • The Medicaid and CHIP Payment and Access Commission (MACPAC) would have to report to Congress within 1 year on how States use utilization management controls for medication‑assisted treatment, including dosing limits, age limits, counseling requirements, psychological screening, and the administrative burden on clinicians and providers.

Personalized for You

How does this bill affect your finances?

Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Free to download

Bill Overview

Analyzed Economic Effects

1 provisions identified: 1 benefits, 0 costs, 0 mixed.

Easier Medicaid access to OUD medicines

If enacted, this bill would require State Medicaid plans and waivers to cover at least one formulation of every drug or biological product used to treat opioid use disorder without prior authorization or dosage limits. If a long‑acting injectable form exists for a drug, the state would have to cover that injectable option. The bill would not stop States from using formularies that follow existing federal rules. These changes would apply to medical assistance provided on or after 1 year after enactment. If a State plan requires State legislation to comply, the plan would not be treated as out of compliance until the first day of the first calendar quarter beginning after the close of the first regular session of the State legislature that begins after enactment; for 2‑year sessions, each year of the session is treated as a separate regular session.

Sponsors & CoSponsors

Sponsor

Hassan, Margaret Wood [D-NH]

NH • D

Cosponsors

  • Sen. Justice, James C. [R-WV]

    WV • R

    Sponsored 12/17/2025

Roll Call Votes

No roll call votes available for this bill.

View on Congress.gov
Back to Legislation